PYC THERAPEUTICS LIMITED (PYC)
Share Price Analysis and Chart

18/07/2024

1

Speculative Buy

$0.17

61.90%

Safety data so far indicates PYC Therapeutics' drug VP-001 is very well tolerated in two trials being conducted on around 18 patients in the US, observes Bell Potter.

While early-stage results, the broker is confident of ongoing positive efficacy and safety updates across the two trials, which are expected to conclude in 2025.

The Speculative Buy rating and 17c target are maintained.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.70 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.00 cents.

01/07/2024

1

Overweight

$0.37

252.38%

As Regulus Therapeutics competes against PYC Therapeutics' asset PYC-003 with its drug asset RGLS8429, Wilsons reviews updated data for the latter's Phase I MAD trial in autosomal dominant polycystic kidney disease (ADPKD).

The Regulus share price reacted negatively on concerns whether the data are clear enough from a regulatory standpoint to continue to progress to a Phase II, explains the broker.

The outcomes of Regulus’ end-of-Phase I meeting with the FDA in the December quarter should provide greater clarity.

The broker maintains an Overweight rating and 37c target.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.80 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.90 cents.